Clinical trials
Recruiting Recurrence trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
540 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2013 | 2 |
| 2014 | 6 |
| 2015 | 3 |
| 2016 | 6 |
| 2017 | 3 |
| 2018 | 11 |
| 2019 | 11 |
| 2020 | 15 |
| 2021 | 28 |
| 2022 | 39 |
| 2023 | 73 |
| 2024 | 113 |
| 2025 | 138 |
| 2026 | 87 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 540 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Memorial Sloan Kettering Cancer Center | 13 |
| Sun Yat-sen University | 9 |
| The First Affiliated Hospital of Soochow University | 9 |
| Beijing Biotech | 8 |
| Fudan University | 7 |
| Institute of Hematology & Blood Diseases Hospital, China | 7 |
| Regeneron Pharmaceuticals | 7 |
| UNC Lineberger Comprehensive Cancer Center | 6 |
| AstraZeneca | 5 |
| Chinese PLA General Hospital | 5 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 540 |
| Multiple Myeloma | 52 |
| Neoplasms | 45 |
| Neoplasm Metastasis | 42 |
| Leukemia, Myeloid, Acute | 37 |
| Lymphoma | 29 |
| Lymphoma, Non-Hodgkin | 24 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 23 |
| Lymphoma, Large B-Cell, Diffuse | 20 |
| Lymphoma, B-Cell | 19 |
Trials
Showing 1 to 25 of 540. Each trial links to its page on Pharma Observatory.
440 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.